Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.

Abstract

OncoGenex Technologies Inc in collaboration with Isis Pharmaceuticals Inc is developing OGX-011, an intravenously administered clusterin-inhibiting antisense oligonucleotide, to potentially sensitize solid tumors that are resistant to conventional cancer therapeutics. Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer.

• Authors: Gerd Schmitz
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 8 Issue 6 Pg. 547-54 (Dec 2006) ISSN: 1464-8431 [Print] England
• PMID: 17243491 (Publication Type: Journal Article, Review)

Chemical References

• CLU protein, human
• Clusterin
• Oligodeoxyribonucleotides, Antisense

Topics

• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clusterin (antagonists & inhibitors, genetics)
• Drug Evaluation, Preclinical
• Female
• Humans
• In Vitro Techniques
• Male
• Neoplasms (genetics, therapy)
• Oligodeoxyribonucleotides, Antisense (chemistry, pharmacokinetics, pharmacology)
• Structure-Activity Relationship